Revenues of the Catalan company AB-BIOTICS increased by 71%

Barcelona (CNA).- The Catalan company AB-BIOTICS, devoted to the protection and distribution of biotechnological solutions to improve health and welfare has presented advance results of its 2010 fiscal year to the Alternative Stock Market, where it quotes since July 2010. The company closed the period with a total income of € 6,162,911, an increase of 71% over the previous year. The CEOs and co-founders of the company, Miquel Angel Bonachera and Sergi Audivert,  explained that given “the national economic situation they can be proud of these results, but AB-BIOTICS aims to become an international reference”.

The economic crisis has not stopped the growth of AB-BIOTICS revenues. This increase is due to expansion in all three business areas in which the company is divided. Firstly, genetics, which basically takes care of pharmacology studies. Secondly, R & D Partnering, which comes from the integrated management of research projects for  the pharmaceutical and food industry. Finally, Functional Ingredients, which develop medical substances (probiotics and other nutraceuticals) to prevent and treat diseases.

However, this is only the beginning of an ambitious scheme. In December 2010, AB-BIOTICS finalized a capital increase of € 4.3 million, which will enable them to implement the first phase of the international expansion plan of the company. The purpose is to be present in various European and American markets with immense potential for its products. Bonachera and Audivert, explained that their “business plan anticipated that most revenue will come from foreign markets over the coming years”.